159 related articles for article (PubMed ID: 38221563)
1. CMTM 6 promotes the development of thyroid cancer by inhibiting NIS activity through activating the MAPK signaling pathway.
Chen X; Shen H; Liu H; Tan L; Zhang N
Funct Integr Genomics; 2024 Jan; 24(1):10. PubMed ID: 38221563
[TBL] [Abstract][Full Text] [Related]
2. OSCC cell-secreted exosomal CMTM6 induced M2-like macrophages polarization via ERK1/2 signaling pathway.
Pang X; Wang SS; Zhang M; Jiang J; Fan HY; Wu JS; Wang HF; Liang XH; Tang YL
Cancer Immunol Immunother; 2021 Apr; 70(4):1015-1029. PubMed ID: 33104837
[TBL] [Abstract][Full Text] [Related]
3. Autophagy-related CMTM6 promotes glioblastoma progression by activating Wnt/β-catenin pathway and acts as an onco-immunological biomarker.
Dai L; Xiao J; Li X; Tao Y; Zhou P; Lyu L; Shi Z; Liang X; Jia Z; Jiang S
J Gene Med; 2024 May; 26(5):e3685. PubMed ID: 38686653
[TBL] [Abstract][Full Text] [Related]
4. Bioinformatics analysis of CMTM family in pan-cancer and preliminary exploration of CMTM6 in bladder cancer.
Xu Y; Li Q; Lin H
Cell Signal; 2024 Mar; 115():111012. PubMed ID: 38113979
[TBL] [Abstract][Full Text] [Related]
5. The BRAFV600E oncogene induces transforming growth factor beta secretion leading to sodium iodide symporter repression and increased malignancy in thyroid cancer.
Riesco-Eizaguirre G; Rodríguez I; De la Vieja A; Costamagna E; Carrasco N; Nistal M; Santisteban P
Cancer Res; 2009 Nov; 69(21):8317-25. PubMed ID: 19861538
[TBL] [Abstract][Full Text] [Related]
6. Switching from MAPK-dependent to MAPK-independent repression of the sodium-iodide symporter in 2D and 3D cultured normal thyroid cells.
Ingeson-Carlsson C; Nilsson M
Mol Cell Endocrinol; 2013 Dec; 381(1-2):241-54. PubMed ID: 23969277
[TBL] [Abstract][Full Text] [Related]
7. Inverse Agonist of Estrogen-Related Receptor γ Enhances Sodium Iodide Symporter Function Through Mitogen-Activated Protein Kinase Signaling in Anaplastic Thyroid Cancer Cells.
Singh TD; Jeong SY; Lee SW; Ha JH; Lee IK; Kim SH; Kim J; Cho SJ; Ahn BC; Lee J; Jeon YH
J Nucl Med; 2015 Nov; 56(11):1690-6. PubMed ID: 26338896
[TBL] [Abstract][Full Text] [Related]
8. CMTM6 promotes migration, invasion, and EMT by interacting with and stabilizing vimentin in hepatocellular carcinoma cells.
Huang X; Xiang L; Wang B; Hu J; Liu C; Ren A; Du K; Ye G; Liang Y; Tang Y; Yang D; Yuan Y
J Transl Med; 2021 Mar; 19(1):120. PubMed ID: 33757532
[TBL] [Abstract][Full Text] [Related]
9. Transmembrane Protein CMTM6 Alleviates Ocular Inflammatory Response and Improves Corneal Epithelial Barrier Function in Experimental Dry Eye.
Zhou Y; Ma B; Liu Q; Duan H; Huo Y; Zhao L; Chen J; Han W; Qi H
Invest Ophthalmol Vis Sci; 2024 Jan; 65(1):4. PubMed ID: 38165704
[TBL] [Abstract][Full Text] [Related]
10. N-cadherin promotes thyroid tumorigenesis through modulating major signaling pathways.
Da C; Wu K; Yue C; Bai P; Wang R; Wang G; Zhao M; Lv Y; Hou P
Oncotarget; 2017 Jan; 8(5):8131-8142. PubMed ID: 28042956
[TBL] [Abstract][Full Text] [Related]
11. CMTM6 as a candidate risk gene for cervical cancer: Comprehensive bioinformatics study.
Huang X; Liu W; Liu C; Hu J; Wang B; Ren A; Huang X; Yuan Y; Liu J; Li M
Front Mol Biosci; 2022; 9():983410. PubMed ID: 36589225
[No Abstract] [Full Text] [Related]
12. HMGB1-mediated autophagy regulates sodium/iodide symporter protein degradation in thyroid cancer cells.
Chai W; Ye F; Zeng L; Li Y; Yang L
J Exp Clin Cancer Res; 2019 Jul; 38(1):325. PubMed ID: 31331356
[TBL] [Abstract][Full Text] [Related]
13. miRNA-106a directly targeting RARB associates with the expression of Na(+)/I(-) symporter in thyroid cancer by regulating MAPK signaling pathway.
Shen CT; Qiu ZL; Song HJ; Wei WJ; Luo QY
J Exp Clin Cancer Res; 2016 Jun; 35(1):101. PubMed ID: 27342319
[TBL] [Abstract][Full Text] [Related]
14. CMTM6 and CMTM4 as two novel regulators of PD-L1 modulate the tumor microenvironment.
Zhang T; Yu H; Dai X; Zhang X
Front Immunol; 2022; 13():971428. PubMed ID: 35958549
[TBL] [Abstract][Full Text] [Related]
15. TBX1 Functions as a Tumor Suppressor in Thyroid Cancer Through Inhibiting the Activities of the PI3K/AKT and MAPK/ERK Pathways.
Wang N; Li Y; Wei J; Pu J; Liu R; Yang Q; Guan H; Shi B; Hou P; Ji M
Thyroid; 2019 Mar; 29(3):378-394. PubMed ID: 30543152
[TBL] [Abstract][Full Text] [Related]
16. CMTM6, a potential immunotherapy target.
Liang J; Li S; Li W; Rao W; Xu S; Meng H; Zhu F; Zhai D; Cui M; Xu D; Cai J; Zhang B
J Cancer Res Clin Oncol; 2022 Jan; 148(1):47-56. PubMed ID: 34783871
[TBL] [Abstract][Full Text] [Related]
17. Kin17 facilitates thyroid cancer cell proliferation, migration, and invasion by activating p38 MAPK signaling pathway.
Jiang QG; Xiong CF; Lv YX
Mol Cell Biochem; 2021 Feb; 476(2):727-739. PubMed ID: 33201383
[TBL] [Abstract][Full Text] [Related]
18. CMTM6 and PD-L1 coexpression is associated with an active immune microenvironment and a favorable prognosis in colorectal cancer.
Peng QH; Wang CH; Chen HM; Zhang RX; Pan ZZ; Lu ZH; Wang GY; Yue X; Huang W; Liu RY
J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33579737
[TBL] [Abstract][Full Text] [Related]
19. Mechanism of RET gene mediated EGFR signaling pathway on epithelial-mesenchymal transition, proliferation and apoptosis of papillary thyroid carcinoma cells.
Zhao YL; Yuan BQ; Shen GS
Eur Rev Med Pharmacol Sci; 2020 Aug; 24(15):8036-8047. PubMed ID: 32767330
[TBL] [Abstract][Full Text] [Related]
20. Knockdown of ANXA10 inhibits proliferation and promotes apoptosis of papillary thyroid carcinoma cells by down-regulating TSG101 thereby inactivating the MAPK/ERK signaling pathway.
Wei T; Zhu X
J Bioenerg Biomembr; 2021 Aug; 53(4):429-440. PubMed ID: 34032966
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
